Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Unii-4mod1f4enc
2. Ko539
3. Ko-539
4. 4mod1f4enc
5. 2134675-36-6
6. Menin-mll Interaction Inhibitor Ko 539
7. (s)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1h-indole-2-carbonitrile
8. 4-methyl-5-[[4-[[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1-[(2s)-2-(4-methylsulfonylpiperazin-1-yl)propyl]indole-2-carbonitrile
9. Ziftomenib [usan]
10. Ko-539;ziftomenibum
11. Ziftomenib [inn]
12. Ko 539 [who-dd]
13. Schembl20846943
14. Gtpl11680
15. Ex-a5611
16. Who 11651
17. Compound 151 [us10781218b2]
18. Hy-132001
19. Cs-0146342
20. 1h-indole-2-carbonitrile, 4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)-1-piperidinyl)methyl)-1-((2s)-2-(4-(methylsulfonyl)-1-piperazinyl)propyl)-
Molecular Weight | 717.9 g/mol |
---|---|
Molecular Formula | C33H42F3N9O2S2 |
XLogP3 | 5.6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 14 |
Rotatable Bond Count | 10 |
Exact Mass | 717.28549845 g/mol |
Monoisotopic Mass | 717.28549845 g/mol |
Topological Polar Surface Area | 159 Ų |
Heavy Atom Count | 49 |
Formal Charge | 0 |
Complexity | 1270 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?